Abstract
Enhancing therapeutic activity against cancer cells and minimizing toxic effects on normal cells are critical elements in chemotherapy. In this issue of Cancer Cell, Leite de Oliveira and colleagues reveal a previously unrecognized role of a prolyl hydroxylase domain in promoting drug delivery to tumors and reducing toxicity in normal organs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
